MYO myomo.com: Likuiditas cepet

Serving as the primary valuation tool, this Myomo, Inc. (MYO) price chart demonstrates the dynamics of a company with a metric of 2.02. The business relies on AI patents and FDA certification, which precludes the emergence of new competitors. Despite challenges with Asian electronics and trade tariffs, demand for robotic orthoses in the US is growing due to the expansion of insurance coverage.

This metric measures the ability of Myomo, Inc. (MYO) to instantaneously settle short-term liabilities by excluding low-liquidity inventories and relying solely on cash and accounts receivable. An analysis of the acid-test ratio confirms that Paul Goodonis's effective management allows Myomo, Inc. (MYO) to maintain financial stability while scaling the production of robotic orthoses, minimizing the risk of cash flow gaps in an environment of expensive borrowed capital.